Prosecution Insights
Last updated: November 20, 2026
Application No. 18/543,921

COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND ANTIOXIDANT SYSTEM

Final Rejection §103§112§DOUBLEPATENT
Filed
Dec 18, 2023
Examiner
WRIGHT, SARAH C
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L'Oréal
OA Round
2 (Final)
42%
Grant Probability
Moderate
3-4
OA Rounds
6m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
242 granted / 575 resolved
-17.9% vs TC avg
Strong +46% interview lift
Without
With
+45.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
48 currently pending
Career history
634
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
55.9%
+15.9% vs TC avg
§102
9.5%
-30.5% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 575 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-13 are pending. Claims 13-14 are newly added. Claims 7, 9 and 12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected groups and species, there being no allowable generic or linking claim Claims 1-6, 8, 10-11 and 13-14 are currently under consideration to the extent that they read upon Applicant’s elected species of emulsion as the single form of the composition, vitamin E as the single antioxidant system, and avobenzone as the single UV filter. Previous Rejections Rejections and/or objections not reiterated from previous office actions are hereby withdrawn as are those rejections and/or objections expressly stated to be withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Objections Withdrawn Specification Objection In light of the amendments to the specification, the objection is withdrawn. Rejections Maintained/New Rejections Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 13 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The response filed 7/21/2026 added claim 13 that introduces NEW MATTER into the claims. The limitation “wherein the composition is free of UV filters which are cinnamic compounds” does not have clear support in the specification and claims as originally filed. There is no disclosure of any intent to exclude UV filters which are cinnamic compounds. Specifically, nowhere in the specification is any intent to exclude UV filters which are cinnamic compounds contained. Examples of cinnamic compounds as UV filters are listed, but are only listed for suitability for inclusion in the invention. There is no discussion of any negative or detrimental effect of cinnamic compounds. While a negative limitation need not be recited in the specification in haec verba, there generally must be something in the specification that conveys to a skilled artisan that the inventor intended the exclusion, such as a discussion of disadvantages or alternatives. Consistent with our precedent in Santarus, Inphi and Nike, the written description requirement cannot be met through simple disregard of the presence or absence of a limitation. Novartis Pharm. Corp. v. Accord Healthcare, Inc. 38 F.4th 1013, 1017 (Fed Cir. 2022) Applicant has not pointed to any disclosure that provides either explicit or implicit support for claim 13 and the phrase ‘wherein the composition is free of UV filters which are cinnamic compounds”. Thus, one skilled in the art would not understand that applicant was not in possession of the currently claimed invention. Obviousness is not the standard for the addition new limitations to the disclosure as filed. It is noted that entitlement to a filing date does not extend to subject matter, which is not disclosed, but would be obvious over what is expressly disclosed. Lockwood v. American Airlines Inc., 41 USPQ2d 1961 (Fed. Cir. 1977). Claim 13 recites limitations, which were not clearly disclosed in the specification as filed, and now change the scope of the instant disclosure as filed. Such limitations recited in claim 13, which did not appear in the specification, as filed, introduce new concepts and violate the description requirement of the first paragraph of 35 U.S.C 112. Applicant is required to provide sufficient written support for the limitations recited in present claim 13 in the specification or claims, as-filed, or remove these limitations from the claim in response to this Office Action. Claim Rejections - 35 USC §112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 14 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 14 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite in reciting "wherein the composition comprises less than 1% by weight relative to the total weight of composition of the antioxidant system." Claim 14 is confusing because nothing is specified as being less than 1% by weight relative to the total weight of composition of the antioxidant system. This phrase is not defined or explained in the specification and cannot be determined by reference to any other claims. As a result, one of ordinary skill in the art would not be reasonably apprised of how to determine what falls within the scope of claim 14. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. The rejection of claims 1-6, 8 and 10-11 under 35 U.S.C. 103 as being unpatentable over Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Berg-Shultz et al. teaches a method of enhancing the photostability of a cinnamate derivative sunscreen in a topical sunscreen composition which comprises including in the sunscreen composition an effective amount of another sunscreen. (See Abstract and claim 1). Bemotrizinol (aka bis-ethylhexyloxyphenol methoxyphenyl triazine or Tinosorb® S) is one such sunscreen that can enhance the photostability of a cinnamate derivative sunscreen, which can be octinoxate. (See Abstract, claim 1 and claim 8 of Berg-Schultz). Berg-Schultz discloses a cosmetic emulsion composition that includes active agent (tocopherol) at 0.1 to 1%, pigments/mineral sunscreens (colorant), avobenzone (Parsol® 1789) at 3 wt% and bemotrizinol (Tinosorb® S) at 5 wt% (see example 2, 9 and paragraphs 30, 32, and 42; instant claims 1, 5, 7, and 9). These amounts and ratios fall within the ranges recited in the instant specification as “effective” for stabilization as called for in instant claims 1 and 5. (See paragraph 77 (about 0.1% to about 10% by weight)). 0.1 to 1% vitamin E (tocopherol) overlaps with the less than 1% called for in instant claim 4 and the less than 1.25% called for in instant claim 3. An encapsulated cinnamate is also present. Encapsulated ethylhexyl cinnamate (octinoxate) is the only particular cinnamate employed in the examples characterizing the stabilizing effect of encapsulating cinnamate compounds which is the focus of Berg-Shultz et al. (see abstract). An emulsion is taught to be a suitable formulation type as called for in claim 8. (See Example 1). Berg-Shultz teaches that octinoxate is stabilized by bemotrizinol. (See claim 8 Berg-Schultz). Additional sunscreen actives (active agent) are present at less than 10 wt% as called for in instant claims 2 and 6. (See 1.8% octocrylene as shown in Table 2 [0065]). While a full example of each embodiment that follows from the teachings of Berg-Shultz et al. is not detailed, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to formulate the active components taught by Berg-Shultz as an emulsion containing (tocopherol) at 0.1 to 1%, pigments/mineral sunscreens (colorant), avobenzone (Parsol® 1789) at 3 wt% and bemotrizinol (Tinosorb® S) at 5 wt% because Berg-Shultz teaches emulsions as a form of its composition and also teaches that bemotrizinol stabilizes other sunscreens such as octinoxate. It also would have been obvious to include a colorant in the sunscreen embodiments because Berg-Shultz suggests to do so. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5, 8-9, and 11 of copending Application No. 18/543,130 (“the ‘130 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, avobenzone and additional active agents and therefore, encompass overlapping or coextensive subject matter. One difference is that claim 1 of the ‘130 Application recites titanium dioxide whereas instant claims don’t recite this limitation. However, instant claims recite the transitional phrase “comprising” which is considered open language and allows the inclusion of additional components, including the titanium dioxide of the ‘130 Application. Another difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘130 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘130 Application to add (tocopherol) at 0.1 to 1% in light of Berg-Shultz teaching that bemotrinzinol stabilizes other components such as sunscreens. The limitations regarding the properties of the composition in claims 2-4 of the ‘130 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-4, 6-7 and 9 of copending Application No. 18/543,141 (“the ‘141 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘141 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘141 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 1-3 of the ‘141 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘141 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-3, 9-11, and 13 of copending Application No. 18/543,157 (“the ‘157 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘157 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘157 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 1-3 of the ‘157 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘157 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 8-9, 13, and 15 of copending Application No. 18/543,287 (“the ‘287 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘287 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘287 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. Therefore, instant claims are obvious over claims of the ‘287 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8, 10-11, and 13 of copending Application No. 18/543,309 (“the ‘309 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘309 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘309 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 1-3 of the ‘309 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘309 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-3, 8, 10-11, and 13 of copending Application No. 18/543,343 (“the ‘343 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘343 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘343 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 1-3 of the ‘343 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘343 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5, 12, and 13 of copending Application No. 18/543,375 (“the ‘375 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘375 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘375 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 2-4 of the ‘375 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘375 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 and 6-8 of copending Application No. 18/543,597 (“the ‘597 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘597 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘597 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. Therefore, instant claims are obvious over claims of the ‘597 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5, 11, and 13 of copending Application No. 18/543,618 (“the ‘618 Application”). in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘618 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘618 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 2-4 of the ‘618 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘618 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5 and 7-8 of copending Application No. 18/543,657 (“the ‘657 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘657 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘657 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 1-3 of the ‘657 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘657 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 4-7, 9, and 11 of copending Application No. 18/543,702 (“the ‘702 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘702 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘702 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 4-6 of the ‘702 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘702 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5 of copending Application No. 18/543,721 (“the ‘721 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘721 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘721 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. Therefore, instant claims are obvious over claims of the ‘721 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 3-5, and 8 of copending Application No. 18/543,756 (“the ‘756 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘756 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘756 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. Therefore, instant claims are obvious over claims of the ‘756 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 6, 8, 11, and 13 of copending Application No. 18/543,860 (“the ‘860 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘860 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘860 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims 6 and 8 of the ‘860 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘860 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2, 6-8, and 11 of copending Application No. 18/543,443 (“the ‘443 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘443 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘443 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. Therefore, instant claims are obvious over claims of the ‘443 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-3 and 8 of copending Application No. 18/985,622 (“the ‘622 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘622 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘622 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. Therefore, instant claims are obvious over claims of the ‘622 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-3 and 6 of copending Application No. 18/985,628 (“the ‘628 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘628 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘628 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. Therefore, instant claims are obvious over claims of the ‘628 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. The provisional rejection of claims 1-6, 8 and 10-11 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5 and 10-12 of copending Application No. 18/985,642 (“the ‘642 Application”) in view of Berg-Shultz et al. (US PGPub No. 2006/0073106) (4/6/2006) is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to a composition comprising bemotrizinol, and therefore, encompass overlapping or coextensive subject matter. One difference is that instant claims recite an antioxidant vitamin E whereas claims of the ‘642 Application do not recite an antioxidant vitamin E. This deficiency is made up for with the teachings of Berg-Shultz. The teachings of Berg-Shultz are described supra. It would be prima facie obvious before the earliest effective filing date for an ordinarily skilled artisan making the composition of the ‘642 Application to add (tocopherol) at 0.1 to 1% as taught by Berg-Shultz in order to have an antioxidant in a composition that Berg-Shultz teaches bemotrinzinol can stabilize other components such as sunscreens. The limitations regarding the properties of the composition in claims of the ‘642 Application are inseparable from the composition and rendered obvious over the same composition recited in the instant claims. Therefore, instant claims are obvious over claims of the ‘642 Application, and they are not patentably distinct over each other. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Response to Arguments Applicants’ comments of July 13, 2026 have been fully reviewed and are found to be unpersuasive as further described below. Applicants argue that it is not clear what Tinosorb S in Example 9 of Berg-Shultz. Berg-Shultz’s Example 9 is silent about what Tinosorb S means. Applicants note that Berg-Shultz’s example 2 refers to “Tinosorb S” as being hydrogenated cocoglycerides. Accordingly it is not clear what ingredient Berg-Shultz used in its examples, and it is not clear that Berg-Shultz used bemotrizinol in its examples instead of hydrogenated cocglycerides, or vice versa. Applicants assert that because of this lack of clarity , no proper rejection can be based on Berg-Shultz or its examples. This is particularly true in light of the claims requirement that bemotrizinol is present in effective amounts. Applicants note that Example 9 contains more than 10% additional UV filters, so the limitations of other claims are not met. Applicants assert that the double patenting rejections all cite Berg-Schultz and repeat the arguments regarding this reference. Applicants arguments have been carefully reviewed and are not found to be persuasive. Applicant is directed to the multiple instances in which Tinorob S is described by the synonym of bemotrizinol. In paragraph [0030] when examples of triazine derivatives are being listed Tinosorb S is referred to as bis ethoxyphenol methoxyphen triazine, which is a synonym for bemotrizinol. Thus, it is obvious that the reference in Example 2 of hydrogenated cocoglycerides is a typographical error, since it is contradicted by other portions of Berg-Schultz. Since it is referred to as an example of a triazine derivative in paragraph [0030], Tinosorb S being referred to as bis ethoxyphenol methoxyphenyl triazine, which is a synonym for bemotrizinol, is deliberate and accurate. Please note that multiple citations were made to the instances in which Tinosorb S is recited in the Berg-Schultz in the Non-Final Rejection of April 7, 2026. Berg-Schultz discloses a cosmetic emulsion composition that includes active agent (tocopherol) at 0.1 to 1%, pigments/mineral sunscreens (colorant), avobenzone (Parsol® 1789) at 3 wt% and bemotrizinol (Tinosorb® S) at 5 wt% (see example 9 and paragraphs 30, 32, and 42; instant claims 1, 5, 7, and 9). Please note that multiple instances are cited in the rejection above in which additional UV filters are present at less than 10 wt%. Additional sunscreen actives (active agent) are present at less than 10 wt% as called for in instant claims 2 and 6. (See 1.8% octocrylene as shown in Table 2 [0065]). Please see the response to the Berg-Schultz arguments regarding the obviousness double patenting rejections. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH CHICKOS whose telephone number is (571)270-3884. The examiner can normally be reached on M-F 9-6. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached on 571-272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SARAH CHICKOS Examiner Art Unit 1619 /DAVID J BLANCHARD/Supervisory Patent Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

Dec 18, 2023
Application Filed
Apr 07, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT
Jul 21, 2026
Response Filed
Nov 03, 2026
Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797326
COSMETIC COMPOSITION COMPRISING FERMENTED CHESTNUT HUSK EXTRACT OR FRACTION THEREOF AS ACTIVE INGREDIENT
3y 11m to grant Granted Nov 17, 2026
Patent 12797316
AEROSOL TYPE COSMETIC HAIR PREPARATION
3y 11m to grant Granted Nov 17, 2026
Patent 12766080
PERSONAL CARE COMPOSITION PRESERVATIVES LEVEL OPTIMIZATION
3y 11m to grant Granted Oct 20, 2026
Patent 12751911
LOW VISCOSITY NONAQUEOUS METAL OXIDE PARTICLE DISPERSIONS AND PROCESSES FOR PREPARING THE SAME
2y 11m to grant Granted Oct 06, 2026
Patent 12740931
COSMETIC OR DERMATOLOGICAL COMPOSITION ACTING IN PARTICULAR ON THE EFFECTS OF BLUE LIGHT ON SKIN AND ITS APPENDAGES, AND ASSOCIATED USES
4y 3m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
42%
Grant Probability
88%
With Interview (+45.8%)
3y 5m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 575 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month